<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143425</url>
  </required_header>
  <id_info>
    <org_study_id>AsanMCHSKim_05</org_study_id>
    <nct_id>NCT04143425</nct_id>
  </id_info>
  <brief_title>Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma</brief_title>
  <official_title>Prospective Observational Study of Imaging-based Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ho Sung Kim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate whether pre-treatment MRI can be used to predict treatment
      response for anti-angiogenic treatment in glioblastomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although overall the effects on prolonging survival in bevacizumab-treated patients is modest
      at best, it is still unclear whether there is not a more substantial positive effect in a
      subset of patients, potentially identifiable by imaging markers. Allowing for prediction of
      good or bad responder from anti-angiogenic therapy prior to treatment completion is important
      to select patients most likely to benefit from anti-angiogenic treatment.

      This is a prospective observational study and no active comparator will be used. Study
      participants include adult patients with recurrent glioblastoma.

      We hypothesized that quantifying changes in multi-modal advanced MR imaging techniques would
      allow early treatment response and long-term prediction in glioblastomas.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Average 9 months</time_frame>
    <description>Time from anti-angiogenic treatment until death or the first imaging report indicating worsening/progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-month progression</measure>
    <time_frame>6 month</time_frame>
    <description>Pathologic confirmation following second look surgery or clinico-radiological assessment at 6-month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Average 12 months</time_frame>
    <description>Time from anti-angiogenic treatment to death</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Adult Glioblastoma</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <condition>Bevacizimab</condition>
  <arm_group>
    <arm_group_label>Received bevacizumab treatment</arm_group_label>
    <description>Recurrent glioblastoma patients with received anti-angiogenic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>3-Tesla conventional magnetic resonance imaging</intervention_name>
    <description>T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging</description>
    <arm_group_label>Received bevacizumab treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Advanced imaging without contrast use</intervention_name>
    <description>Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy</description>
    <arm_group_label>Received bevacizumab treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dynamic susceptibility contrast-weighted imaging</intervention_name>
    <description>Cerebral blood volume and vessel architectural imaging parameters</description>
    <arm_group_label>Received bevacizumab treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of tertiary medical center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients had histologically confirmed glioblastoma with progression diagnosed on the
             basis of clinical data and MRI after standard treatment of operation, concurrent
             chemoradiotherapy, and adjuvant temozolomide;

          2. Patients were more than 3 months from chemoradiotherapy to avoid the confounding
             factor of radiation necrosis (pseudoprogression);

          3. Ability to understand and the willingness to sign a written informed consent document;
             all patients, or their legal guardians, must sign a written informed consent and
             Health Insurance Portability and Accountability Act (HIPAA) authorization in
             accordance with institutional guidelines

        Exclusion Criteria:

          1. Patients were not subject to therapies other than anti-angiogenic treatment, including
             re-operation, re-irradiation, or immunotherapies, because of the patient's clinical
             status and indication

          2. Patients who have any type of bioimplant activated by mechanical, electronic, or
             magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators,
             electronic infusion pumps, etc), because such devices may be displaced or malfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Sung Kim, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiology, Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Eun Park, M.D.,Ph.D.</last_name>
    <phone>82230101505</phone>
    <email>jieunp@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Min Jae Kim, M.D.</last_name>
    <phone>821029424084</phone>
    <email>manzae.kim@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Pope WB, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ, Huo J, Brown MS, Goldin J, Cloughesy T. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 2011 Feb 1;76(5):432-7. doi: 10.1212/WNL.0b013e31820a0a8a.</citation>
    <PMID>21282590</PMID>
  </reference>
  <results_reference>
    <citation>Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 1;23(19):5745-5756. doi: 10.1158/1078-0432.CCR-16-2844. Epub 2017 Jun 27.</citation>
    <PMID>28655794</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol. 2015 Aug;17(8):1148-56. doi: 10.1093/neuonc/nou364. Epub 2015 Feb 2.</citation>
    <PMID>25646027</PMID>
  </results_reference>
  <results_reference>
    <citation>Park JE, Kim HS, Park KJ, Kim SJ, Kim JH, Smith SA. Pre- and Posttreatment Glioma: Comparison of Amide Proton Transfer Imaging with MR Spectroscopy for Biomarkers of Tumor Proliferation. Radiology. 2016 Feb;278(2):514-23. doi: 10.1148/radiol.2015142979. Epub 2015 Aug 19.</citation>
    <PMID>26491847</PMID>
  </results_reference>
  <results_reference>
    <citation>Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK, Sorensen AG. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med. 2013 Sep;19(9):1178-83. doi: 10.1038/nm.3289. Epub 2013 Aug 18.</citation>
    <PMID>23955713</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 27, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Ho Sung Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Recurrent Glioblastoma; Bevacizumab; Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data sharing if raw imaging data outside Korea is prohibited by Korean government. For anonymized imaging data, part of cases may be feasible on the approval of the principle investigator.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

